Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Harith Adnan

Critical Care Medicine Toledo, OH Medical Doctor

NPI 1417454257 CMS profile 11650882

2222 Cherry St Ste 1400, Toledo, OH 43608

Open in the dashboard

General payments

$4,079

11 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harith Adnan of Toledo, OH is reported in the CMS Open Payments database as having received $4,079 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,955 7
2024 General $57 3
2023 General $67 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harith Adnan
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Harith Adnan were reported at $3,955. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Harith Adnan Critical Care Medicine median Middle half National median
2019 $0 $149 $51–$535 $163
2020 $0 $110 $30–$325 $114
2021 $0 $125 $34–$403 $132
2022 $0 $157 $49–$582 $149
2023 $67 $162 $56–$621 $160
2024 $57 $168 $53–$634 $164
2025 $3,955 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Intuitive Surgical, Inc. $3,955 7 payments
  2. GlaxoSmithKline, LLC. $67 1 payment
  3. Actelion Pharmaceuticals US, Inc. $23 1 payment
  4. Inspire Medical Systems, Inc. $18 1 payment
  5. Pfizer Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Education $2,500 1 payment
  2. Travel and Lodging $1,455 6 payments
  3. Food and Beverage $124 4 payments
Products named General payments · program years 2023–2025
  1. Da Vinci Surgical System $3,955 7 payments
  2. AREXVY $67 1 payment
  3. OPSUMIT $23 1 payment
  4. UPTRAVI $23 1 payment
  5. INSPIRE $18 1 payment
  6. ELIQUIS $16 1 payment
  7. NURTEC ODT $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

809

Median for Pulmonary Disease: 936

Drug cost

$197,299

Median for Pulmonary Disease: $487,987

Branded share of claims

67.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 140 $103,139
Spiriva Respimat Tiotropium Bromide Brand 30 $19,664
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 31 $18,608
Breo Ellipta Fluticasone/Vilanterol Brand 27 $13,917
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 20 $9,267
Incruse Ellipta Umeclidinium Bromide Brand 15 $8,746
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 29 $7,752
Albuterol Sulfate Hfa Albuterol Sulfate Brand 168 $5,917
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 29 $3,907
Ventolin Hfa Albuterol Sulfate Brand 28 $2,538

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$46,957

Medicare's payments for the services billed

Medicare patients

211

Average age 73

Services billed

498

101 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 60%
Ischemic heart disease 57%
Arthritis 56%
Heart failure 55%
Diabetes 45%
Atrial fibrillation 45%
Chronic kidney disease 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $11
$11 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $11
$11 — —
ELIQUIS
  • PFIZER INC. $8
$8 — —
NURTEC ODT
  • PFIZER INC. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record